GlassScriptPhysician profile
Edward J Kata
NPI 1467497586
$4,538.03
in general payments reported to CMS, 2019-2025
24 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $255 · 2021: $235 · 2022: $535 · 2023: $598 · 2024: $727 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Education: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.78 |
| Education | $459.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,282.88 | 2019-2020 | |
| Astellas Pharma US INC | $886.22 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $441.47 | 2022-2025 | |
| Medtronic, INC. | $366.99 | 2021-2025 | Interstim |
| Procept Biorobotics Corporation | $233.38 | 2022-2025 | Aquabeam Robotic System |
| Abbvie INC. | $179.38 | 2022-2025 | |
| Boston Scientific Corporation | $136.07 | 2020-2025 | Ams 700, Lithovue |
| Endo Pharmaceuticals INC. | $135.42 | 2022-2024 | Xiaflex, Aveed |
| Teleflex LLC | $122.07 | 2023-2024 | Urolift |
| Endo USA, INC. | $109.61 | 2024-2025 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $107.89 | 2022-2025 | |
| Urogen Pharma, INC. | $105.68 | 2022-2024 | Jelmyto |
| Janssen Biotech, INC. | $97.85 | 2022-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $48.02 | 2024 | Prolaris |
| Sumitomo Pharma America, INC. | $44.42 | 2023-2024 | Orgovyx, Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $42.50 | 2022 | |
| Allergan, INC. | $41.72 | 2019-2020 | |
| Urovant Sciences INC | $34.44 | 2022 | |
| Antares Pharma, INC. | $32.05 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Abc Home Medical Supply, INC. | $30.01 | 2023 | |
| Merck Sharp & Dohme LLC | $18.15 | 2023 | Lynparza, Keytruda |
| Alnylam Pharmaceuticals INC. | $17.53 | 2023 | Givlaari |
| 180 Medical, INC. | $12.78 | 2022 | |
| Clarus Therapeutics INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.